Skip to main content
Erschienen in: Clinical Research in Cardiology 6/2019

21.12.2018 | Original Paper

Prognostic impact of chronic kidney disease and renal replacement therapy in ventricular tachyarrhythmias and aborted cardiac arrest

verfasst von: Kathrin Weidner, Michael Behnes, Tobias Schupp, Jonas Rusnak, Linda Reiser, Gabriel Taton, Thomas Reichelt, Dominik Ellguth, Niko Engelke, Armin Bollow, Ibrahim El-Battrawy, Uzair Ansari, Jorge Hoppner, Christoph A. Nienaber, Kambis Mashayekhi, Christel Weiß, Muharrem Akin, Martin Borggrefe, Ibrahim Akin

Erschienen in: Clinical Research in Cardiology | Ausgabe 6/2019

Einloggen, um Zugang zu erhalten

Abstract

Background

The study sought to assess the prognostic impact of chronic kidney disease (CKD) and renal replacement therapy (RRT) in patients with ventricular tachyarrhythmias and sudden cardiac arrest (SCA) on admission.

Methods

A large retrospective registry was used including all consecutive patients presenting with ventricular tachycardia (VT), fibrillation (VF) and SCA on admission from 2002 to 2016. Non-CKD vs. “CKD without RRT”, and “CKD without RRT” vs. “CKD with RRT” were compared applying multivariable Cox regression models and propensity-score matching for evaluation of the primary prognostic endpoint defined as long-term all-cause mortality at 2 years. Secondary prognostic endpoints were cardiac death at 24 h, in-hospital death at index and the composite endpoint of recurrent ventricular tachyarrhythmias, appropriate ICD therapies and cardiac death at 24 h.

Results

In 2686 unmatched high-risk patients with ventricular tachyarrhythmias and SCA, non-CKD was present in 46%, “CKD without RRT” in 46% and “CKD with RRT” in 8%. Each, VT and VF occurred in about one-third of CKD patients. Multivariable Cox regression models revealed that “CKD without RRT” (HR = 2.118; p = 0.001) and “CKD with RRT” (HR = 3.043; p = 0.001) patients were associated with the primary endpoint of long-term mortality at 2 years, which was also proven after propensity-score matching (non-CKD vs. “CKD without RRT”: 43% vs. 27%, log rank p = 0.001; HR = 1.847; “CKD without RRT” vs. “CKD with RRT”: 74% vs. 51%, log rank p = 0.001; HR = 2.129). The rates of secondary endpoints were higher for cardiac death at 24 h, in-hospital death at index and the composite of recurrent ventricular tachyarrhythmias, appropriate ICD therapies and  cardiac death at 24 h, respectively, for “CKD without RRT” and “CKD with RRT” patients. 

Conclusion

In patients presenting with ventricular tachyarrhythmias and aborted SCA on admission, the presence of CKD, especially combined with RRT, is independently associated with an increase of long-term all-cause mortality at 2 years, cardiac death at 24 h, in-hospital death and the composite of recurrent ventricular tachyarrhythmias, appropriate ICD therapies and  cardiac death at 24 h.
Literatur
1.
Zurück zum Zitat Green D, New RP, Kalra D (2011) Sudden cardiac death in hamodialysis patients—an in depth review Am J Kidney Dis 57:921–929 P.CrossRefPubMed Green D, New RP, Kalra D (2011) Sudden cardiac death in hamodialysis patients—an in depth review Am J Kidney Dis 57:921–929 P.CrossRefPubMed
2.
Zurück zum Zitat Singh TK, Arya V, Navaratnarajah N (2014) Chronic kidney disease and cardiovascular disease: a focus on primary care. Cardiovasc Hematol Disord Drug Targets 14(3):212–218CrossRefPubMed Singh TK, Arya V, Navaratnarajah N (2014) Chronic kidney disease and cardiovascular disease: a focus on primary care. Cardiovasc Hematol Disord Drug Targets 14(3):212–218CrossRefPubMed
3.
Zurück zum Zitat Emrich IE et al (2018) Symmetric dimethylarginine (SDMA) outperforms asymmetric dimethylarginine (ADMA) and other methylarginines as predictor of renal and cardiovascular outcome in non-dialysis chronic kidney disease. Clin Res Cardiol 107(3):201–213CrossRefPubMed Emrich IE et al (2018) Symmetric dimethylarginine (SDMA) outperforms asymmetric dimethylarginine (ADMA) and other methylarginines as predictor of renal and cardiovascular outcome in non-dialysis chronic kidney disease. Clin Res Cardiol 107(3):201–213CrossRefPubMed
4.
Zurück zum Zitat Amann K (2008) Media calcification and intima calcification are distinct entities in chronic kidney disease. Clin J Am Soc Nephrol 3(6):1599–1605CrossRefPubMed Amann K (2008) Media calcification and intima calcification are distinct entities in chronic kidney disease. Clin J Am Soc Nephrol 3(6):1599–1605CrossRefPubMed
5.
Zurück zum Zitat Olgaard K, Lewin E, Silver J (2011) Calcimimetics, vitamin D and ADVANCE in the management of CKD-MBD. Nephrol Dial Transpl 26(4):1117–1119CrossRef Olgaard K, Lewin E, Silver J (2011) Calcimimetics, vitamin D and ADVANCE in the management of CKD-MBD. Nephrol Dial Transpl 26(4):1117–1119CrossRef
6.
Zurück zum Zitat Shivendra S (2014) Cardiovascular disease in chronic kidney disease. Nephrology (3):20–29 Shivendra S (2014) Cardiovascular disease in chronic kidney disease. Nephrology (3):20–29
7.
8.
Zurück zum Zitat Haider AW et al (1998) Increased left ventricular mass and hypertrophy are associated with increased risk for sudden death. J Am Coll Cardiol 32(5):1454–1459CrossRefPubMed Haider AW et al (1998) Increased left ventricular mass and hypertrophy are associated with increased risk for sudden death. J Am Coll Cardiol 32(5):1454–1459CrossRefPubMed
9.
Zurück zum Zitat Ukena C et al (2016) Renal denervation for treatment of ventricular arrhythmias: data from an International Multicenter Registry. Clin Res Cardiol 105(10):873–879CrossRefPubMed Ukena C et al (2016) Renal denervation for treatment of ventricular arrhythmias: data from an International Multicenter Registry. Clin Res Cardiol 105(10):873–879CrossRefPubMed
10.
Zurück zum Zitat Rigopoulos AG et al (2016) Low occurrence of ventricular arrhythmias after alcohol septal ablation in high-risk patients with hypertrophic obstructive cardiomyopathy. Clin Res Cardiol 105(11):953–961CrossRefPubMed Rigopoulos AG et al (2016) Low occurrence of ventricular arrhythmias after alcohol septal ablation in high-risk patients with hypertrophic obstructive cardiomyopathy. Clin Res Cardiol 105(11):953–961CrossRefPubMed
11.
Zurück zum Zitat Franczyk-Skora B et al (2015) Sudden cardiac death in CKD patients. Int Urol Nephrol 47(6):971–982CrossRefPubMed Franczyk-Skora B et al (2015) Sudden cardiac death in CKD patients. Int Urol Nephrol 47(6):971–982CrossRefPubMed
12.
Zurück zum Zitat Bleyer AJ et al (2006) Characteristics of sudden death in hemodialysis patients. Kidney Int 69(12):2268–2273CrossRefPubMed Bleyer AJ et al (2006) Characteristics of sudden death in hemodialysis patients. Kidney Int 69(12):2268–2273CrossRefPubMed
13.
Zurück zum Zitat Burghardt A et al (2018) Risk marker profiles in patients treated with percutaneous septal ablation for symptomatic hypertrophic obstructive cardiomyopathy. Clin Res Cardiol 107(6):479–486CrossRefPubMed Burghardt A et al (2018) Risk marker profiles in patients treated with percutaneous septal ablation for symptomatic hypertrophic obstructive cardiomyopathy. Clin Res Cardiol 107(6):479–486CrossRefPubMed
14.
Zurück zum Zitat Sedaghat-Hamedani F et al (2018) Clinical outcomes associated with sarcomere mutations in hypertrophic cardiomyopathy: a meta-analysis on 7675 individuals. Clin Res Cardiol 107(1):30–41CrossRefPubMed Sedaghat-Hamedani F et al (2018) Clinical outcomes associated with sarcomere mutations in hypertrophic cardiomyopathy: a meta-analysis on 7675 individuals. Clin Res Cardiol 107(1):30–41CrossRefPubMed
15.
Zurück zum Zitat Frommeyer G et al (2016) Long-term follow-up of subcutaneous ICD systems in patients with hypertrophic cardiomyopathy: a single-center experience. Clin Res Cardiol 105(1):89–93CrossRefPubMed Frommeyer G et al (2016) Long-term follow-up of subcutaneous ICD systems in patients with hypertrophic cardiomyopathy: a single-center experience. Clin Res Cardiol 105(1):89–93CrossRefPubMed
18.
Zurück zum Zitat Yousuf O et al (2015) Clinical management and prevention of sudden cardiac death. Circ Res 116(12):2020–2040CrossRefPubMed Yousuf O et al (2015) Clinical management and prevention of sudden cardiac death. Circ Res 116(12):2020–2040CrossRefPubMed
19.
Zurück zum Zitat Priori SG et al (2016) 2015 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death. The Task Force for the Management of Patients with Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death of the European Society of Cardiology. G Ital Cardiol (Rome) 17(2):108–170 Priori SG et al (2016) 2015 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death. The Task Force for the Management of Patients with Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death of the European Society of Cardiology. G Ital Cardiol (Rome) 17(2):108–170
20.
Zurück zum Zitat Marx N et al (2018) Mechanisms of cardiovascular complications in chronic kidney disease: research focus of the Transregional Research Consortium SFB TRR219 of the University Hospital Aachen (RWTH) and the Saarland University. Clin Res Cardiol 107(Suppl 2):120–126CrossRefPubMed Marx N et al (2018) Mechanisms of cardiovascular complications in chronic kidney disease: research focus of the Transregional Research Consortium SFB TRR219 of the University Hospital Aachen (RWTH) and the Saarland University. Clin Res Cardiol 107(Suppl 2):120–126CrossRefPubMed
21.
Zurück zum Zitat Stahli BE et al (2017) Outcomes of patients with periprocedural atrial fibrillation undergoing percutaneous coronary intervention for chronic total occlusion. Clin Res Cardiol 106(12):986–994CrossRefPubMed Stahli BE et al (2017) Outcomes of patients with periprocedural atrial fibrillation undergoing percutaneous coronary intervention for chronic total occlusion. Clin Res Cardiol 106(12):986–994CrossRefPubMed
22.
Zurück zum Zitat Coiro S et al (2017) Association of digitalis treatment with outcomes following myocardial infarction in patients with heart failure or evidence of left ventricular dysfunction: an analysis from the high-risk myocardial infarction database initiative. Clin Res Cardiol 106(9):722–733CrossRefPubMed Coiro S et al (2017) Association of digitalis treatment with outcomes following myocardial infarction in patients with heart failure or evidence of left ventricular dysfunction: an analysis from the high-risk myocardial infarction database initiative. Clin Res Cardiol 106(9):722–733CrossRefPubMed
23.
Zurück zum Zitat Zannad F, Rossignol P, Cardiovascular outcome trials in patients with advanced kidney disease time for action. Circulation 2017. 135:1769–1771CrossRef Zannad F, Rossignol P, Cardiovascular outcome trials in patients with advanced kidney disease time for action. Circulation 2017. 135:1769–1771CrossRef
24.
Zurück zum Zitat Zannad F, Rossignol P (2017) Cardiovascular outcome trials in patients with advanced kidney disease: time for action. Circulation 135(19):1769–1771CrossRefPubMed Zannad F, Rossignol P (2017) Cardiovascular outcome trials in patients with advanced kidney disease: time for action. Circulation 135(19):1769–1771CrossRefPubMed
25.
Zurück zum Zitat National Kidney F (2015) KDOQI clinical practice guideline for hemodialysis adequacy: 2015 update. Am J Kidney Dis 66(5):884–930CrossRef National Kidney F (2015) KDOQI clinical practice guideline for hemodialysis adequacy: 2015 update. Am J Kidney Dis 66(5):884–930CrossRef
26.
Zurück zum Zitat Priori SG et al (2015) ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: The Task Force for the Management of Patients with Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death of the European Society of Cardiology (ESC). Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC). Eur Heart J 2015. 36(41):2793–2867CrossRefPubMed Priori SG et al (2015) ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: The Task Force for the Management of Patients with Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death of the European Society of Cardiology (ESC). Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC). Eur Heart J 2015. 36(41):2793–2867CrossRefPubMed
27.
Zurück zum Zitat Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD Work Group (2009) KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD). Kidney Int Suppl 76(113):S1–S130 Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD Work Group (2009) KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD). Kidney Int Suppl 76(113):S1–S130
28.
Zurück zum Zitat Andrassy KM (2013) Comments on ‘KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease’. Kidney Int 84(3):622–623CrossRefPubMed Andrassy KM (2013) Comments on ‘KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease’. Kidney Int 84(3):622–623CrossRefPubMed
29.
Zurück zum Zitat Ferdinand D, Otto M, Weiss C (2016) Get the most from your data: a propensity score model comparison on real-life data. Int J Gen Med 9:123–131CrossRefPubMedPubMedCentral Ferdinand D, Otto M, Weiss C (2016) Get the most from your data: a propensity score model comparison on real-life data. Int J Gen Med 9:123–131CrossRefPubMedPubMedCentral
30.
Zurück zum Zitat Austin PC (2011) An introduction to propensity score methods for reducing the effects of confounding in observational studies. Multivariate Behav Res 46(3):399–424CrossRefPubMedPubMedCentral Austin PC (2011) An introduction to propensity score methods for reducing the effects of confounding in observational studies. Multivariate Behav Res 46(3):399–424CrossRefPubMedPubMedCentral
31.
Zurück zum Zitat Shastri S et al (2012) Predictors of sudden cardiac death: a competing risk approach in the hemodialysis study. Clin J Am Soc Nephrol 7(1):123–130CrossRefPubMed Shastri S et al (2012) Predictors of sudden cardiac death: a competing risk approach in the hemodialysis study. Clin J Am Soc Nephrol 7(1):123–130CrossRefPubMed
32.
Zurück zum Zitat Baigent C et al (2011) The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial. Lancet 377(9784):2181–2192CrossRefPubMedPubMedCentral Baigent C et al (2011) The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial. Lancet 377(9784):2181–2192CrossRefPubMedPubMedCentral
33.
Zurück zum Zitat Sherif KA et al (2014) Cardiac repolarization abnormalities among patients with various stages of chronic kidney disease. Clin Cardiol 37(7):417–421CrossRefPubMedPubMedCentral Sherif KA et al (2014) Cardiac repolarization abnormalities among patients with various stages of chronic kidney disease. Clin Cardiol 37(7):417–421CrossRefPubMedPubMedCentral
34.
Zurück zum Zitat Dinshaw L et al (2018) The T-peak-to-T-end interval: a novel ECG marker for ventricular arrhythmia and appropriate ICD therapy in patients with hypertrophic cardiomyopathy. Clin Res Cardiol 107(2):130–137CrossRefPubMed Dinshaw L et al (2018) The T-peak-to-T-end interval: a novel ECG marker for ventricular arrhythmia and appropriate ICD therapy in patients with hypertrophic cardiomyopathy. Clin Res Cardiol 107(2):130–137CrossRefPubMed
35.
36.
Zurück zum Zitat Fort J, Chronic renal failure: a cardiovascular risk factor. Kidney Int Suppl 2005(99):S25–s29 Fort J, Chronic renal failure: a cardiovascular risk factor. Kidney Int Suppl 2005(99):S25–s29
37.
Zurück zum Zitat Schiffrin EL, Lipman ML, Mann JF (2007) Chronic kidney disease: effects on the cardiovascular system. Circulation 116(1):85–97CrossRefPubMed Schiffrin EL, Lipman ML, Mann JF (2007) Chronic kidney disease: effects on the cardiovascular system. Circulation 116(1):85–97CrossRefPubMed
38.
Zurück zum Zitat Kayvanpour E et al (2017) Genotype-phenotype associations in dilated cardiomyopathy: meta-analysis on more than 8000 individuals. Clin Res Cardiol 106(2):127–139CrossRefPubMed Kayvanpour E et al (2017) Genotype-phenotype associations in dilated cardiomyopathy: meta-analysis on more than 8000 individuals. Clin Res Cardiol 106(2):127–139CrossRefPubMed
39.
Zurück zum Zitat Chua HC et al (2018) Unexplained cardiac arrest: a tale of conflicting interpretations of KCNQ1 genetic test results. Clin Res Cardiol 107(8):670–678CrossRefPubMed Chua HC et al (2018) Unexplained cardiac arrest: a tale of conflicting interpretations of KCNQ1 genetic test results. Clin Res Cardiol 107(8):670–678CrossRefPubMed
40.
Zurück zum Zitat Writing Committee M et al (2013) 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. Circulation 128(16):e240–e327 Writing Committee M et al (2013) 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. Circulation 128(16):e240–e327
41.
Zurück zum Zitat Priori SG, Blomstrom-Lundqvist C (2015) European Society of Cardiology Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death summarized by co-chairs. Eur Heart J 36(41):2757–2759CrossRefPubMed Priori SG, Blomstrom-Lundqvist C (2015) European Society of Cardiology Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death summarized by co-chairs. Eur Heart J 36(41):2757–2759CrossRefPubMed
42.
Zurück zum Zitat Bettin M et al (2018) Right versus left parasternal electrode position in the entirely subcutaneous ICD. Clin Res Cardiol 107(5):389–394CrossRefPubMed Bettin M et al (2018) Right versus left parasternal electrode position in the entirely subcutaneous ICD. Clin Res Cardiol 107(5):389–394CrossRefPubMed
44.
Zurück zum Zitat Kobe J et al (2017) Posttraumatic stress and quality of life with the totally subcutaneous compared to conventional cardioverter-defibrillator systems. Clin Res Cardiol 106(5):317–321CrossRefPubMed Kobe J et al (2017) Posttraumatic stress and quality of life with the totally subcutaneous compared to conventional cardioverter-defibrillator systems. Clin Res Cardiol 106(5):317–321CrossRefPubMed
45.
Zurück zum Zitat Erath JW et al (2017) The wearable cardioverter-defibrillator in a real-world clinical setting: experience in 102 consecutive patients. Clin Res Cardiol 106(4):300–306CrossRefPubMed Erath JW et al (2017) The wearable cardioverter-defibrillator in a real-world clinical setting: experience in 102 consecutive patients. Clin Res Cardiol 106(4):300–306CrossRefPubMed
46.
Zurück zum Zitat Wolff G et al (2017) Implantable cardioverter/defibrillators for primary prevention in dilated cardiomyopathy post-DANISH: an updated meta-analysis and systematic review of randomized controlled trials. Clin Res Cardiol 106(7):501–513CrossRefPubMed Wolff G et al (2017) Implantable cardioverter/defibrillators for primary prevention in dilated cardiomyopathy post-DANISH: an updated meta-analysis and systematic review of randomized controlled trials. Clin Res Cardiol 106(7):501–513CrossRefPubMed
48.
Zurück zum Zitat Linz D et al (2016) Impact of obstructive and central apneas on ventricular repolarisation: lessons learned from studies in man and pigs. Clin Res Cardiol 105(8):639–647CrossRefPubMed Linz D et al (2016) Impact of obstructive and central apneas on ventricular repolarisation: lessons learned from studies in man and pigs. Clin Res Cardiol 105(8):639–647CrossRefPubMed
49.
Zurück zum Zitat Duncker D et al (2014) Risk for ventricular fibrillation in peripartum cardiomyopathy with severely reduced left ventricular function-value of the wearable cardioverter/defibrillator. Eur J Heart Fail 16(12):1331–1336CrossRefPubMed Duncker D et al (2014) Risk for ventricular fibrillation in peripartum cardiomyopathy with severely reduced left ventricular function-value of the wearable cardioverter/defibrillator. Eur J Heart Fail 16(12):1331–1336CrossRefPubMed
50.
Zurück zum Zitat Lachmann V et al (2017) Aborted sudden cardiac death: ICD or no ICD. Clin Res Cardiol 106(9):760–763CrossRefPubMed Lachmann V et al (2017) Aborted sudden cardiac death: ICD or no ICD. Clin Res Cardiol 106(9):760–763CrossRefPubMed
51.
Zurück zum Zitat Shen L et al (2017) Declining risk of sudden death in heart failure. N Engl J Med 377(1):41–51CrossRefPubMed Shen L et al (2017) Declining risk of sudden death in heart failure. N Engl J Med 377(1):41–51CrossRefPubMed
52.
Zurück zum Zitat De Bie MK et al (2008) Prevention of sudden cardiac death: rationale and design of the implantable cardioverter defibrillators in Dialysis patients (ICD2) TRIAL–a prospective pilot study. Curr Med Res Opin 24(8):2151–2157CrossRefPubMed De Bie MK et al (2008) Prevention of sudden cardiac death: rationale and design of the implantable cardioverter defibrillators in Dialysis patients (ICD2) TRIAL–a prospective pilot study. Curr Med Res Opin 24(8):2151–2157CrossRefPubMed
Metadaten
Titel
Prognostic impact of chronic kidney disease and renal replacement therapy in ventricular tachyarrhythmias and aborted cardiac arrest
verfasst von
Kathrin Weidner
Michael Behnes
Tobias Schupp
Jonas Rusnak
Linda Reiser
Gabriel Taton
Thomas Reichelt
Dominik Ellguth
Niko Engelke
Armin Bollow
Ibrahim El-Battrawy
Uzair Ansari
Jorge Hoppner
Christoph A. Nienaber
Kambis Mashayekhi
Christel Weiß
Muharrem Akin
Martin Borggrefe
Ibrahim Akin
Publikationsdatum
21.12.2018
Verlag
Springer Berlin Heidelberg
Erschienen in
Clinical Research in Cardiology / Ausgabe 6/2019
Print ISSN: 1861-0684
Elektronische ISSN: 1861-0692
DOI
https://doi.org/10.1007/s00392-018-1396-y

Weitere Artikel der Ausgabe 6/2019

Clinical Research in Cardiology 6/2019 Zur Ausgabe

Die „Zehn Gebote“ des Endokarditis-Managements

30.04.2024 Endokarditis Leitlinie kompakt

Worauf kommt es beim Management von Personen mit infektiöser Endokarditis an? Eine Kardiologin und ein Kardiologe fassen die zehn wichtigsten Punkte der neuen ESC-Leitlinie zusammen.

Strenge Blutdruckeinstellung lohnt auch im Alter noch

30.04.2024 Arterielle Hypertonie Nachrichten

Ältere Frauen, die von chronischen Erkrankungen weitgehend verschont sind, haben offenbar die besten Chancen, ihren 90. Geburtstag zu erleben, wenn ihr systolischer Blutdruck < 130 mmHg liegt. Das scheint selbst für 80-Jährige noch zu gelten.

Sind Frauen die fähigeren Ärzte?

30.04.2024 Gendermedizin Nachrichten

Patienten, die von Ärztinnen behandelt werden, dürfen offenbar auf bessere Therapieergebnisse hoffen als Patienten von Ärzten. Besonders gilt das offenbar für weibliche Kranke, wie eine Studie zeigt.

Dihydropyridin-Kalziumantagonisten können auf die Nieren gehen

30.04.2024 Hypertonie Nachrichten

Im Vergleich zu anderen Blutdrucksenkern sind Kalziumantagonisten vom Diyhdropyridin-Typ mit einem erhöhten Risiko für eine Mikroalbuminurie und in Abwesenheit eines RAS-Blockers auch für ein terminales Nierenversagen verbunden.

Update Kardiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.